← Leaderboards
Peter Palese
Mount Sinai School Of Medicine Of Nyu
$42,879,921
Attributed
$46,648,514
Total exposure
21
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $5.6M · FY2005–25$10M$7.5M$5M$2.5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$80,585,726 · 24
CDC$508,500 · 1
By mechanism
P01$33,137,718 · 11
U19$15,262,118 · 5
R01$12,396,094 · 3
T32$8,426,678 · 1
U01$7,949,429 · 2
U54$2,917,189 · 1
Top collaborators
- Jeffrey Victor Ravetch10 shared
- Raymond F. Schinazi1 shared
Most similar at Mount Sinai School Of Medicine Of Nyu
Same institution · by research overlap
- Charlotte Cunningham-Rundles$20,851,703
- Maria Cecilia Berin$11,924,488
- Anne Moscona$28,223,876
- Anna Halina Nowak-Wegrzyn$5,307,777
- Maria-Arantxa Arantxa Horga$584,772
Others in their field
Top investigators on “Virus”
- David Heimbrook · Leidos Biomedical Research, Inc.$512,873,478
- Lawrence Corey · Fred Hutchinson Cancer Center$392,679,667
- Barton F Haynes · Duke University$328,711,626
- Dennis R. Burton · Scripps Research Institute$276,624,892
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Richard Webby · St. Jude Children'S Research Hospital$265,067,789
Research focus
VirusVaccinesInfluenzavirusAntibodiesBaseIn VivoImmune ResponseInfluenza Virus VaccineVaccinationInfluenzaHemagglutininCollaborationsProteinsResponseViralMonoclonal AntibodiesEpitopesAntigensHumoral ImmunitiesSiteImmunityProgramsDesignGenerations
Grant awards (138)
Development of vaccination strategies to elicit broadly protective immunity against influenza$845,133
R01 · FY2025 · AI
Development of vaccination strategies to elicit broadly protective immunity against influenza$862,508
R01 · FY2024 · AI
Development of vaccination strategies to elicit broadly protective immunity against influenza$847,458
R01 · FY2023 · AI
Toward a Universal Influenza Virus Vaccine$1,829,781
P01 · FY2022 · AI · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$847,458
R01 · FY2022 · AI
Optimization of novel immunogen design to elicit broadly protective immune responses against influenza viruses$437,036
P01 · FY2022 · AI · contact PI
Administrative Core$173,995
P01 · FY2022 · AI · contact PI
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection$130,823
R01 · FY2022 · AI
Toward a Universal Influenza Virus Vaccine$1,816,495
P01 · FY2021 · AI · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$847,458
R01 · FY2021 · AI
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection$784,941
R01 · FY2021 · AI
Optimization of novel immunogen design to elicit broadly protective immune responses against influenza viruses$423,750
P01 · FY2021 · AI · contact PI
Administrative Core$173,995
P01 · FY2021 · AI · contact PI
Toward a Universal Influenza Virus Vaccine$1,803,471
P01 · FY2020 · AI · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$847,458
R01 · FY2020 · AI
Evaluation of the FcgR mechanisms in the antibody-dependent enhancement of SARS-CoV-2 infection$654,116
R01 · FY2020 · AI
Optimization of novel immunogen design to elicit broadly protective immune responses against influenza viruses$423,750
P01 · FY2020 · AI · contact PI
Administrative Core$160,971
P01 · FY2020 · AI · contact PI
Toward a Universal Influenza Virus Vaccine$1,790,702
P01 · FY2019 · AI · contact PI
Development of vaccination strategies to elicit broadly protective immunity against influenza$864,833
R01 · FY2019 · AI
Training Program in Mechanisms of Virus-Host Interactions$577,718
T32 · FY2019 · AI · contact PI
Optimization of novel immunogen design to elicit broadly protective immune responses against influenza viruses$421,880
P01 · FY2019 · AI · contact PI
Administrative Core$150,072
P01 · FY2019 · AI · contact PI
RespiDART: Frontiers in Drug Development against Respiratory Viruses$5,000
R13 · FY2019 · AI
Mechanisms of broadly neutralizing humoral immunity against influenza viruses$1,918,351
U19 · FY2018 · AI · contact PI
Toward a Universal Influenza Virus Vaccine$1,802,510
P01 · FY2018 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$561,172
T32 · FY2018 · AI · contact PI
Characterization of Cross-Reactive Immune Responses Against Influenza Virus Surf$424,434
U19 · FY2018 · AI · contact PI
Optimization of novel immunogen design to elicit broadly protective immune responses against influenza viruses$423,750
P01 · FY2018 · AI · contact PI
Reagent Core$215,812
U19 · FY2018 · AI · contact PI
Administrative Core$135,685
P01 · FY2018 · AI · contact PI
Administrative Core$93,520
U19 · FY2018 · AI · contact PI
Mechanisms of broadly neutralizing humoral immunity against influenza viruses$1,918,351
U19 · FY2017 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$548,009
T32 · FY2017 · AI · contact PI
Characterization of Cross-Reactive Immune Responses Against Influenza Virus Surf$424,435
U19 · FY2017 · AI · contact PI
Reagent Core$215,812
U19 · FY2017 · AI · contact PI
Administrative Core$93,520
U19 · FY2017 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$1,365
T32 · FY2017 · AI · contact PI
Mechanisms of broadly neutralizing humoral immunity against influenza viruses$1,918,351
U19 · FY2016 · AI · contact PI
Toward a Universal Influenza Virus Vaccine$1,770,560
P01 · FY2016 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$523,884
T32 · FY2016 · AI · contact PI
Design of New Immunogens Based on Conserved Epitopes in the Influenza Virus Hemagglutinin$322,706
P01 · FY2016 · AI · contact PI
Characterization of Cross-Reactive Immune Responses Against Influenza Virus Surf$296,983
U19 · FY2016 · AI · contact PI
Reagent Core$151,006
U19 · FY2016 · AI · contact PI
Administrative Core$150,792
P01 · FY2016 · AI · contact PI
Administrative Core$65,437
U19 · FY2016 · AI · contact PI
Design of New Immunogens Based on Conserved Epitopes in the Influenza Virus Hemagglutinin$43,799
P01 · FY2016 · AI · contact PI
Toward a Universal Influenza Virus Vaccine$43,799
P01 · FY2016 · AI · contact PI
Mechanisms of broadly neutralizing humoral immunity against influenza viruses$1,918,351
U19 · FY2015 · AI · contact PI
Toward a Universal Influenza Virus Vaccine$1,694,246
P01 · FY2015 · AI · contact PI
Training Program in Mechanisms of Virus-Host Interactions$518,465
T32 · FY2015 · AI · contact PI
Characterization of Cross-Reactive Immune Responses Against Influenza Virus Surf$424,434
U19 · FY2015 · AI · contact PI
Design of New Immunogens Based on Conserved Epitopes in the Influenza Virus Hemagglutinin$319,710
P01 · FY2015 · AI · contact PI
Reagent Core$215,812
U19 · FY2015 · AI · contact PI
Administrative Core$93,520
U19 · FY2015 · AI · contact PI
Administrative Core$89,520
P01 · FY2015 · AI · contact PI
Mechanisms of broadly neutralizing humoral immunity against influenza viruses$1,953,101
U19 · FY2014 · AI · contact PI
Toward a Universal Influenza Virus Vaccine$1,694,246
P01 · FY2014 · AI · contact PI
TRAINING PROGRAM IN MECHANISMS OF VIRUS-HOST INTERACTIONS$511,376
T32 · FY2014 · AI · contact PI
Design of New Immunogens Based on Conserved Epitopes in the Influenza Virus Hemagglutinin$417,168
P01 · FY2014 · AI · contact PI
Characterization of Cross-Reactive Immune Responses Against Influenza Virus Surf$302,360
U19 · FY2014 · AI · contact PI
Reagent Core$153,742
U19 · FY2014 · AI · contact PI
Administrative Core$116,808
P01 · FY2014 · AI · contact PI
Administrative Core$66,622
U19 · FY2014 · AI · contact PI
Toward a Universal Influenza Virus Vaccine$1,592,593
P01 · FY2013 · AI · contact PI
TRAINING PROGRAM IN MECHANISMS OF VIRUS-HOST INTERACTIONS$569,279
T32 · FY2013 · AI · contact PI
Live, recombinant newcastle disease virus-based vaccine against high pri pathoge$374,960
U54 · FY2013 · AI · contact PI
Design of New Immunogens Based on Conserved Epitopes in the Influenza Virus...$299,093
P01 · FY2013 · AI · contact PI
Administrative Core$83,929
P01 · FY2013 · AI · contact PI
Toward a Universal Influenza Virus Vaccine$1,728,808
P01 · FY2012 · AI · contact PI
TRAINING PROGRAM IN MECHANISMS OF VIRUS-HOST INTERACTIONS$574,679
T32 · FY2012 · AI · contact PI
Live, recombinant newcastle disease virus-based vaccine against high pri pathoge$374,462
U54 · FY2012 · AI · contact PI
Design of New Immunogens Based on Conserved Epitopes in the Influenza Virus...$324,719
P01 · FY2012 · AI · contact PI
Administrative Core$91,123
P01 · FY2012 · AI · contact PI
NOVEL CELLULAR AND VIRAL TARGETS FOR ANTI-INFLUENZA VIRUS DRUGS$1,427,583
U01 · FY2011 · AI · contact PI
TRAINING PROGRAM IN MECHANISMS OF VIRUS-HOST INTERACTIONS$507,873
T32 · FY2011 · AI · contact PI
Live, recombinant newcastle disease virus-based vaccine against high pri pathoge$449,475
U54 · FY2011 · AI · contact PI
NOVEL CELLULAR AND VIRAL TARGETS FOR ANTI-INFLUENZA VIRUS DRUGS$1,460,196
U01 · FY2010 · AI · contact PI
Live, recombinant newcastle disease virus-based vaccine against high pri pathoge$926,528
U54 · FY2010 · AI · contact PI
DEVELOPMENT OF A UNIVERSAL INFLUENZA VIRUS VACCINE$500,000
RC1 · FY2010 · AI · contact PI
TRAINING PROGRAM IN MECHANISMS OF VIRUS-HOST INTERACTIONS$489,067
T32 · FY2010 · AI · contact PI
NOVEL CELLULAR AND VIRAL TARGETS FOR ANTI-INFLUENZA VIRUS DRUGS$1,435,679
U01 · FY2009 · AI · contact PI
Live, recombinant newcastle disease virus-based vaccine against high pri pathoge$791,764
U54 · FY2009 · AI · contact PI
DEVELOPMENT OF A UNIVERSAL INFLUENZA VIRUS VACCINE$500,000
RC1 · FY2009 · AI · contact PI
Anti-IFN Activity of SARS Virus and SARS Vaccines$407,700
P01 · FY2009 · AI · contact PI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$380,061
T32 · FY2009 · AI · contact PI
NOVEL CELLULAR AND VIRAL TARGETS FOR ANTI-INFLUENZA VIRUS DRUGS$1,397,389
U01 · FY2008 · AI · contact PI
Inhibition of Host Innate Immune Response by Nipah Virus$473,777
U19 · FY2008 · AI · contact PI
Anti-IFN Activity of SARS Virus and SARS Vaccines$395,887
P01 · FY2008 · AI · contact PI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$331,675
T32 · FY2008 · AI · contact PI
Replicative and Pro-Apoptotic Factors of the 1918 Flu$158,157
P01 · FY2008 · AI · contact PI
NOVEL CELLULAR AND VIRAL TARGETS FOR ANTI-INFLUENZA VIRUS DRUGS$1,720,082
U01 · FY2007 · AI · contact PI
Inhibition of Host Innate Immune Response by Nipah Virus$473,991
U19 · FY2007 · AI · contact PI
Anti-IFN Activity of SARS Virus and SARS Vaccines$400,107
P01 · FY2007 · AI · contact PI
Development of Guinea Pig as Mamalian for Influenza Virus Transmission$254,250
U01 · FY2007 · CI · contact PI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$237,668
T32 · FY2007 · AI · contact PI
Replicative and Pro-Apoptotic Factors of the 1918 Flu$157,139
P01 · FY2007 · AI · contact PI
IMPACT OF RESPIRATORY RNA VIRUSES ON CELLULAR PATHWAYS$584,295
P01 · FY2006 · AI · contact PI
Inhibition of Host Innate Immune Response by Nipah Virus$491,681
U19 · FY2006 · AI · contact PI
INFLUENZA VIRUS RIBONUCLEOPROTEINS (RNP)$413,792
R01 · FY2006 · AI · contact PI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$375,330
T32 · FY2006 · AI · contact PI
Anti-IFN Activity of SARS Virus and SARS Vaccines$371,075
P01 · FY2006 · AI · contact PI
Development of Guinea Pig as Mamalian for Influenza Virus Transmission$254,250
U01 · FY2006 · CI · contact PI
Replicative and Pro-Apoptotic Factors of the 1918 Flu$161,581
P01 · FY2006 · AI · contact PI
IMPACT OF RESPIRATORY RNA VIRUSES ON CELLULAR PATHWAYS$598,357
P01 · FY2005 · AI
Inhibition of Host Innate Immune Response by Nipah Virus$483,391
U19 · FY2005 · AI
INFLUENZA VIRUS RIBONUCLEOPROTEINS (RNP)$423,750
R01 · FY2005 · AI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$371,021
T32 · FY2005 · AI
Anti-IFN Activity of SARS Virus and SARS Vaccines$293,805
P01 · FY2005 · AI
Replicative and Pro-Apoptotic Factors of the 1918 Flu$157,446
P01 · FY2005 · AI
IMPACT OF RESPIRATORY RNA VIRUSES ON CELLULAR PATHWAYS$598,357
P01 · FY2004 · AI
Inhibition of Host Innate Immune Response by Nipah Virus$475,324
U19 · FY2004 · AI
INFLUENZA VIRUS RIBONUCLEOPROTEINS (RNP)$423,750
R01 · FY2004 · AI
INFLUENZA VIRUS TRANSFECTANTS: PROBES FOR VIRAL &CELL.$417,414
R01 · FY2004 · AI
Replicative and Pro-Apoptotic Factors of the 1918 Flu$181,888
P01 · FY2004 · AI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$135,784
T32 · FY2004 · AI
IMPACT OF RESPIRATORY RNA VIRUSES ON CELLULAR PATHWAYS$1,098,305
P01 · FY2003 · AI
EVASION OF HOST IMMUNE RESPONSE BY INFLUENZA VIRUS$818,463
P01 · FY2003 · AI
INFLUENZA VIRUS RIBONUCLEOPROTEINS (RNP)$423,750
R01 · FY2003 · AI
INFLUENZA VIRUS TRANSFECTANTS: PROBES FOR VIRAL &CELL.$407,427
R01 · FY2003 · AI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$322,500
T32 · FY2003 · AI
EVASION OF HOST IMMUNE RESPONSE BY INFLUENZA VIRUS$1,370,577
P01 · FY2002 · AI
IMPACT OF RESPIRATORY RNA VIRUSES ON CELLULAR PATHWAYS$545,315
P01 · FY2002 · AI
INFLUENZA VIRUS RIBONUCLEOPROTEINS (RNP)$423,750
R01 · FY2002 · AI
INFLUENZA VIRUS TRANSFECTANTS: PROBES FOR VIRAL &CELL.$401,208
R01 · FY2002 · AI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$323,113
T32 · FY2002 · AI
INFLUENZA A AND A VIRUSES WITH MODIFIED NS1 GENE$149,825
P01 · FY2002 · AI
Influenza Virus Mediated Modulation of Gene Expression$0
P01 · FY2002 · AI
EVASION OF HOST IMMUNE RESPONSE BY INFLUENZA VIRUS$889,201
P01 · FY2001 · AI
INFLUENZA VIRUS TRANSFECTANTS: PROBES FOR VIRAL &CELL.$399,349
R01 · FY2001 · AI
GENETIC ANALYSIS OF INFLUENZA A, B AND C VIRUSES$370,701
R01 · FY2001 · AI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$295,583
T32 · FY2001 · AI
INFLUENZA A AND A VIRUSES WITH MODIFIED NS1 GENE$149,825
P01 · FY2001 · AI
EVASION OF HOST IMMUNE RESPONSE BY INFLUENZA VIRUS$749,126
P01 · FY2000 · AI
INFLUENZA VIRUS TRANSFECTANTS: PROBES FOR VIRAL &CELL.$390,119
R01 · FY2000 · AI
GENETIC ANALYSIS OF INFLUENZA A, B AND C VIRUSES$368,898
R01 · FY2000 · AI
TRAINING PROGRAM: MECHANISMS OF VIRUS-HOST INTERACTIONS$271,056
T32 · FY2000 · AI
INFLUENZA A AND A VIRUSES WITH MODIFIED NS1 GENE$149,825
P01 · FY2000 · AI